Business Description
![Bio-Rad Laboratories Inc Bio-Rad Laboratories Inc logo](https://static.gurufocus.com/logos/0C000006XD.png?14)
Bio-Rad Laboratories Inc
NAICS : 334516
SIC : 3826
ISIN : US0905722072
Share Class Description:
STU:BUWA: Class ADescription
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.16 | |||||
Equity-to-Asset | 0.7 | |||||
Debt-to-Equity | 0.21 | |||||
Debt-to-EBITDA | -0.91 | |||||
Interest Coverage | 6.74 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 2.99 | |||||
Beneish M-Score | -2.47 | |||||
WACC vs ROIC |
Growth Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 2.7 | |||||
3-Year EPS without NRI Growth Rate | 3.5 | |||||
3-Year FCF Growth Rate | -22.1 | |||||
3-Year Book Growth Rate | -2.5 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 1.91 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 50.99 | |||||
9-Day RSI | 53.77 | |||||
14-Day RSI | 54.14 | |||||
6-1 Month Momentum % | -3.88 | |||||
12-1 Month Momentum % | -18.49 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.28 | |||||
Quick Ratio | 4.63 | |||||
Cash Ratio | 3.32 | |||||
Days Inventory | 242.62 | |||||
Days Sales Outstanding | 66.33 | |||||
Days Payable | 39.33 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 1.5 | |||||
Shareholder Yield % | 3.35 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 53.97 | |||||
Operating Margin % | 12.97 | |||||
Net Margin % | -51.73 | |||||
FCF Margin % | 6.94 | |||||
ROE % | -16 | |||||
ROA % | -11.34 | |||||
ROIC % | 2.63 | |||||
3-Year ROIIC % | 6.18 | |||||
ROC (Joel Greenblatt) % | -102.04 | |||||
ROCE % | -15.04 | |||||
Years of Profitability over Past 10-Year | 8 |
GF Value Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 29.47 | |||||
PE Ratio without NRI | 30.55 | |||||
Shiller PE Ratio | 16.67 | |||||
PS Ratio | 3.71 | |||||
PB Ratio | 1.38 | |||||
Price-to-Tangible-Book | 1.54 | |||||
Price-to-Free-Cash-Flow | 53.61 | |||||
Price-to-Operating-Cash-Flow | 27.48 | |||||
EV-to-EBIT | -5.34 | |||||
EV-to-Forward-EBIT | 24.03 | |||||
EV-to-EBITDA | -5.86 | |||||
EV-to-Forward-EBITDA | 17.76 | |||||
EV-to-Revenue | 3.5 | |||||
EV-to-Forward-Revenue | 3.33 | |||||
EV-to-FCF | 50.6 | |||||
Price-to-Projected-FCF | 1.13 | |||||
Price-to-Median-PS-Value | 0.97 | |||||
Price-to-Graham-Number | 1.45 | |||||
Price-to-Net-Current-Asset-Value | 63.63 | |||||
Earnings Yield (Greenblatt) % | -18.73 | |||||
FCF Yield % | 1.93 | |||||
Forward Rate of Return (Yacktman) % | 22.99 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bio-Rad Laboratories Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 2,372.044 | ||
EPS (TTM) (€) | -43.929 | ||
Beta | 1.4 | ||
Volatility % | 43.9 | ||
14-Day RSI | 54.14 | ||
14-Day ATR (€) | 5.098545 | ||
20-Day SMA (€) | 290.635 | ||
12-1 Month Momentum % | -18.49 | ||
52-Week Range (€) | 242.7 - 355.2 | ||
Shares Outstanding (Mil) | 27.87 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Bio-Rad Laboratories Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Bio-Rad Laboratories Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Bio-Rad Laboratories Inc Frequently Asked Questions
What is Bio-Rad Laboratories Inc(STU:BUWA)'s stock price today?
The current price of STU:BUWA is €294.60. The 52 week high of STU:BUWA is €355.20 and 52 week low is €242.70.
When is next earnings date of Bio-Rad Laboratories Inc(STU:BUWA)?
The next earnings date of Bio-Rad Laboratories Inc(STU:BUWA) is 2024-10-25 Est..
Does Bio-Rad Laboratories Inc(STU:BUWA) pay dividends? If so, how much?
Bio-Rad Laboratories Inc(STU:BUWA) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |